Grants Awarded

Apogee Biotechnology Corporation has recently been awarded research grants from two prestigious institutions.

The first grant, a Phase II Small Business Innovation Research grant, is from the National Eye Institute.

This grant, in the amount of $1.9 million, will fund preclinical studies of Apogee’s sphingosine kinase inhibitor platform in models of retinopathy.

The second grant, a Phase II Small Business Innovation Research grant, is awarded from the National Institute of Diabetes and Digestive and Kidney Diseases.

This award, in the amount of $1.7 million dollars, will fund the preclinical development of Apogee’s sphingosine kinase inhibitor platform toward clinical trials in ulcerative colitis.

Powered by THE BRAVO GROUP & ARCHODA: CREATE SOMETHING UNIQUE